ES2528363T3 - Tratamiento para el cáncer - Google Patents

Tratamiento para el cáncer Download PDF

Info

Publication number
ES2528363T3
ES2528363T3 ES05813351.3T ES05813351T ES2528363T3 ES 2528363 T3 ES2528363 T3 ES 2528363T3 ES 05813351 T ES05813351 T ES 05813351T ES 2528363 T3 ES2528363 T3 ES 2528363T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
alkenylalkyl
cycloalkenylalkyl
cycloalkylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05813351.3T
Other languages
English (en)
Inventor
David L. Morris
Mohammad Hossein Pourgholami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pitney Pharmaceuticals Pty Ltd
Original Assignee
Pitney Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004906983A external-priority patent/AU2004906983A0/en
Application filed by Pitney Pharmaceuticals Pty Ltd filed Critical Pitney Pharmaceuticals Pty Ltd
Application granted granted Critical
Publication of ES2528363T3 publication Critical patent/ES2528363T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Al menos un taxoide en una cantidad efectiva y al menos un compuesto carbamato de benzimidazol de fórmula I:**Fórmula** en la que R1 se selecciona de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, -SR7, -SOR8, -SO2R9, -SCN, B'(CH2)nBR10, -C(O)-R11 o -OR12, COOR13, -NO2, NR13aCOOR13b, isotiocianato o -CN donde R7 a R13b se seleccionan cada uno independientemente de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, B y B' se seleccionan independientemente de O, S, S(O) o SO2 y n es de 1 a 4; R2 se selecciona de H o alquilo sustituido o no sustituido; R3 se selecciona de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, anillo heterocíclico de 5 o 6 miembros, cuyo(s) heteroátomo(s) se selecciona(n) de uno o más de O, S y/o N, -SR14, -OR15, -SOR16, -SO2R17, -SCN, -C(O)-R18, - OR19, NR20COOR21, en donde R15 a R21 cada uno se selecciona independientemente de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo o arilalquilo; en una cantidad efectiva para su uso en el tratamiento de un tumor de ovario en un sujeto.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES05813351.3T 2004-12-06 2005-12-06 Tratamiento para el cáncer Expired - Lifetime ES2528363T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004906983A AU2004906983A0 (en) 2004-12-06 Treatment for cancer
AU2004906983 2004-12-06
PCT/AU2005/001839 WO2006060853A1 (en) 2004-12-06 2005-12-06 Treatment for cancer

Publications (1)

Publication Number Publication Date
ES2528363T3 true ES2528363T3 (es) 2015-02-09

Family

ID=36577596

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05813351.3T Expired - Lifetime ES2528363T3 (es) 2004-12-06 2005-12-06 Tratamiento para el cáncer

Country Status (9)

Country Link
US (2) US20090286838A1 (es)
EP (1) EP1830847B1 (es)
JP (1) JP2008522984A (es)
KR (1) KR101287917B1 (es)
CN (1) CN101111248A (es)
CA (1) CA2589828C (es)
ES (1) ES2528363T3 (es)
PT (1) PT1830847E (es)
WO (1) WO2006060853A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
KR20090046142A (ko) 2007-11-05 2009-05-11 삼성전자주식회사 입력 필체 자동 변환 시스템 및 방법
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
WO2010135534A2 (en) * 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
WO2011041914A1 (en) * 2009-10-09 2011-04-14 University Health Network (Uhn) Use of flubendazole and vinca alkaloids for treatment of hematological diseases
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP3202397B1 (en) 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
CN103054858A (zh) * 2013-01-21 2013-04-24 杭州雷索药业有限公司 奥苯达唑在制备抗血管生成类药物中的应用
US9833431B2 (en) * 2013-11-01 2017-12-05 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer
CA3087226A1 (en) * 2019-07-18 2021-01-18 Nano Targeting & Therapy Biopharma Inc. Drug delivery by pore-modified mesoporous silica nanoparticles
CN111388469B (zh) * 2019-10-21 2021-11-02 温州医科大学 一种芬苯达唑在制备抗肿瘤药物中的应用
PL4048284T3 (pl) * 2019-10-21 2025-11-03 Acura Nanomedicine Corporation Metoda leczenia nowotworów
KR102516896B1 (ko) * 2020-10-19 2023-04-03 고려대학교 산학협력단 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
CN113648308A (zh) * 2021-09-14 2021-11-16 东莞市人民医院 奥芬达唑作为抗卵巢癌药物的应用
FR3151700A1 (fr) 2023-07-28 2025-01-31 Soitec Procédé de fabrication d’un substrat de diamant ou d’un matériau III-V pour applications en microélectronique
CN118908896B (zh) * 2024-09-02 2026-01-06 广东海洋大学 4-（1H-苯并[d]咪唑-2-基）-N，N-双（2-氯乙基）苯胺衍生物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900429A (en) * 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US20010047021A1 (en) 2000-04-28 2001-11-29 The Procter & Gamble Company Cancer treatment
WO2002067932A1 (en) 2001-01-11 2002-09-06 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
EP1379242B1 (en) * 2001-03-26 2012-08-15 Newsouth Innovations Pty Limited Method for treatment of cancer and compositions for use therein
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Also Published As

Publication number Publication date
EP1830847A1 (en) 2007-09-12
US20120214856A1 (en) 2012-08-23
KR101287917B1 (ko) 2013-07-23
US8835478B2 (en) 2014-09-16
JP2008522984A (ja) 2008-07-03
KR20070112113A (ko) 2007-11-22
CA2589828C (en) 2014-07-08
EP1830847A4 (en) 2012-09-12
PT1830847E (pt) 2015-02-05
WO2006060853A1 (en) 2006-06-15
EP1830847B1 (en) 2014-11-19
US20090286838A1 (en) 2009-11-19
CA2589828A1 (en) 2006-06-15
CN101111248A (zh) 2008-01-23

Similar Documents

Publication Publication Date Title
PE20241625A1 (es) Combinaciones farmaceuticas de inhibidores de sos1 para tratar o prevenir cancer
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
RU2485104C2 (ru) Новые производные 1,2-дигидрохинолина, обладающие активностью связывания глюкокортикоидного рецептора
RU2416603C9 (ru) Производные аминодигидротиазина
RU2004127925A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
RU2008144805A (ru) Применение биарилкарбоксамидов в лечении заболеваний, связанных с hedgehog-путем
AR054799A1 (es) Derivados de oxindol
RU2001121138A (ru) Ингибиторы тромбина
BR112022001931A2 (pt) Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
RU2004117545A (ru) Аминопиримидины и пиридины
RU2006112593A (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk
PE20010932A1 (es) N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida inhibidores de cinasas dependientes de ciclina
AR048361A1 (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
PE20110294A1 (es) Compuestos heterociclicos como inhibidores de enzimas de senal especifica
ATE270103T1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
PE20141827A1 (es) Inhibidores de proteinas quinasas
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
EA200600509A1 (ru) Соединения пиримидотиофена
RU2006147267A (ru) Конденсированное гетероциклическое соединение
RU2007132670A (ru) Индолин-сульфонамидные соединения
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
RU2350609C2 (ru) Производные бензофурана и бензотиофена, применяемые при лечении гиперпролиферативных заболеваний
WO2009118297A3 (en) Pesticidal active mixtures comprising aminothiazoline compounds